Evaluation of the Safety of Olprinone for Low Central Venous Pressure Management during Open Hepatectomy
- Conditions
- Hepatocellular carcinoma, Intrahepatic cholangiocarcinoma, Metastatic liver cancer, Perihilar cholan
- Registration Number
- JPRN-jRCTs041230111
- Lead Sponsor
- Sugiura Teiichi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
(1) An open hepatectomy is scheduled.
(2) The registered age is between 18 and 75 years old.
(3) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is 0 or 1.
(4) There's no obstructive ventilatory impairment (Forced Expiratory Volume in 1 second (FEV1.0%) is >= 70%).
(5) There's no history of angina or myocardial infar ction.
(6) No moderate to severe valvular disease (based on the findings from a transthoracic echocardiogram).
(7) All the following conditions are met:
White blood cell count: between 2,500/mm3 and 10,000/mm3
Platelet count >=100,000/mm3
AST <=100IU/L
ALT <=100IU/L
Total bilirubin <=2.0 mg/dL (<=4.0mg/dL in cases with jaundice)
Serum creatinine <=1.0mg/dL
(8) Written consent for trial participation has been obtained from the patient.
(1) Cases with a history of arrhythmia. (Premature ventricular contractions are not included.)
(2) Cases where surgery is conducted without discontinuing antiplatelet drugs.
(3) Cases with a history of hypersensitivity to PDEIII inhibitors.
(4) Cases deemed unsuitable for this trial by the at tending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method